About Ipca Laboratories Limited
Data last updated: 04 January 2026
Ipca Laboratories Limited is a public limited company based in Mumbai, Maharashtra, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 19 October 1949, the company has been in operation for over 77 years.
Registered with ROC Mumbai under CIN L24239MH1949PLC007837. Listed on BSE: 524494 and NSE: IPCALAB.
Capital: an authorised share capital of ₹57.6 Cr and a paid-up capital of ₹25.37 Cr. Formerly known as The Indian Pharmaceutical Combine Association Ltd. It is led by directors including Vivek Keshav Shiralkar and Pranay Premchand Godha.
Last AGM: 11 August 2025. Financial statements filed for year ended 31 March 2025. Office: 48 Kandivli Industrialestate Kandivali (W), Mumbai, Maharashtra, India – 400067.
As per the financials filed for FY 2025, the company reported a revenue of ₹9,032.39 Cr, a growth of 15% compared to the previous year.
The company has a workforce of approximately 17,422 employees as per the latest available data. Its group structure includes 3 subsidiaries and 2 joint ventures.
The company is associated with 2 brands - Ipca Laboratories, Ipca Laboratories. As per MCA filings, the company has open charges of ₹2,708.14 Cr and satisfied charges of ₹2,002.16 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website ipca.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered Address48 Kandivli Industrialestate Kandivali (W), Mumbai, Maharashtra, India – 400067
-
IndustryPharma, Drug Formulation & Development, API Manufacturers
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Associated Brands with Ipca Laboratories Limited
Ipca Laboratories Limited operates two associated brands: Ipca Laboratories and Ipca Laboratories. These brands represent Ipca Laboratories Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| APIs and drug formulations are manufactured for therapeutic segments. | ipca.com | |
| Ipca Laboratories is engaged in pharmaceutical manufacturing and distribution. | ipcalabs.com |
Business Activity of Ipca Laboratories Limited
Ipca Laboratories Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Ipca Laboratories Limited
Ipca Laboratories Limited is audited by NVC & Associates LLp (ICAI peer reviewed, certificate valid till 2027-07-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| NVC & Associates LLp (ICAI peer reviewed, certificate valid till 2027-07-31) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Ipca Laboratories Limited
Ipca Laboratories Limited is currently managed by 9 directors, with 18 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Vivek Keshav Shiralkar
Also directs:
Kewal Kiran Clothing Limited, Opec Investment Pvt Ltd
|
Director | 29 May 2024 | 2 Years 1 Months | Current |
|
Pranay Premchand Godha
Also directs:
Xgrow Traders Llp, Kaygee Laboratories Private Limited, Kaygee Investments Private Limited and 2 more
|
Managing Director | 30 Jul 2009 | 16 Years 11 Months | Current |
| Prashant Premchand Godha | Director | 28 Jul 2011 | 14 Years 11 Months | Current |
| Harish Pandurang Kamath | Nodal Officer | 28 Aug 2019 | 6 Years 10 Months | Current |
|
Narendra Mairpady
Also directs:
Kesar Enterprises Limited, Saatvik Green Energy Limited, Equippp Social Impact Technologies Limited and 5 more
|
Director | 20 Oct 2022 | 3 Years 8 Months | Current |
| Premchand Gigalal Godha | Whole-Time Director | 31 Jan 2012 | 14 Years 5 Months | Current |
Financials of Ipca Laboratories Limited FY 2026 filings available
Ipca Laboratories Limited reported revenue of ₹9,646.33 Cr (up 7.91% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹9,646.33 Cr | ₹8,939.59 Cr | ₹7,705.04 Cr | ₹6,244.32 Cr | ₹5,829.79 Cr | ₹5,419.99 Cr | ₹4,648.71 Cr |
| Other Income | ₹174.45 Cr | ₹92.8 Cr | ₹124.77 Cr | ₹125.62 Cr | ₹66.57 Cr | ₹62.84 Cr | ₹67 Cr |
| Total Income | ₹9,820.78 Cr | ₹9,032.39 Cr | ₹7,829.81 Cr | ₹6,369.94 Cr | ₹5,896.36 Cr | ₹5,482.83 Cr | ₹4,715.71 Cr |
| Cost of Materials Consumed | ₹2,344.01 Cr | ₹2,276.82 Cr | ₹2,216.32 Cr | ₹1,708.65 Cr | ₹1,664.2 Cr | ₹1,597.14 Cr | ₹1,460.37 Cr |
| Purchases of Stock-in-Trade | ₹532.62 Cr | ₹547.78 Cr | ₹490.07 Cr | ₹497.19 Cr | ₹480.3 Cr | ₹325.95 Cr | ₹359.88 Cr |
| Changes in Inventories | -₹53.91 Cr | -₹46.05 Cr | -₹130.64 Cr | ₹100.67 Cr | -₹129.65 Cr | -₹194.79 Cr | -₹176.12 Cr |
| Employee Benefit Expense | ₹2,160.2 Cr | ₹1,983.99 Cr | ₹1,708.43 Cr | ₹1,287.64 Cr | ₹1,177.39 Cr | ₹1,013.57 Cr | ₹921.23 Cr |
| Finance Costs | ₹75.94 Cr | ₹84.93 Cr | ₹138.27 Cr | ₹45.54 Cr | ₹7.69 Cr | ₹9.04 Cr | ₹16.5 Cr |
| Depreciation & Amortisation | ₹418.12 Cr | ₹397.82 Cr | ₹357.24 Cr | ₹261.56 Cr | ₹232.42 Cr | ₹209.17 Cr | ₹210.5 Cr |
| Other Expenses | ₹2,684.85 Cr | ₹2,450.91 Cr | ₹2,099.7 Cr | ₹1,723.4 Cr | ₹1,328.29 Cr | ₹1,133.77 Cr | ₹1,176.65 Cr |
| Total Expenses | ₹8,161.83 Cr | ₹7,696.2 Cr | ₹6,879.39 Cr | ₹5,624.65 Cr | ₹4,760.64 Cr | ₹4,093.85 Cr | ₹3,969.01 Cr |
| Profit Before Exceptional Items & Tax | ₹1,658.95 Cr | ₹1,336.19 Cr | ₹950.42 Cr | ₹745.29 Cr | ₹1,135.72 Cr | ₹1,388.98 Cr | ₹746.7 Cr |
| Exceptional Items | -₹86.43 Cr | -₹205.05 Cr | -₹107.75 Cr | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹1,572.52 Cr | ₹1,131.14 Cr | ₹842.67 Cr | ₹745.29 Cr | ₹1,135.72 Cr | ₹1,388.98 Cr | ₹746.7 Cr |
| Total Tax Expense | ₹381.15 Cr | ₹343.61 Cr | ₹313.46 Cr | ₹253.36 Cr | ₹224.27 Cr | ₹240.14 Cr | ₹135.33 Cr |
| Net Profit | ₹1,183.78 Cr | ₹785.24 Cr | ₹522.92 Cr | ₹478.99 Cr | ₹889.79 Cr | ₹1,141.14 Cr | ₹603.56 Cr |
| attributable to Owners | ₹1,141.12 Cr | ₹737.68 Cr | ₹547.35 Cr | ₹471.32 Cr | ₹884.08 Cr | ₹1,140.01 Cr | ₹606.32 Cr |
| attributable to NCI | ₹42.66 Cr | ₹47.56 Cr | -₹24.43 Cr | ₹7.67 Cr | ₹5.71 Cr | ₹1.13 Cr | -₹2.76 Cr |
| Other Comprehensive Income | ₹42.76 Cr | -₹24.55 Cr | -₹9.45 Cr | ₹7.34 Cr | ₹3 Cr | -₹40 Lakh | ₹3.53 Cr |
| Total Comprehensive Income | ₹1,226.54 Cr | ₹760.69 Cr | ₹513.47 Cr | ₹486.33 Cr | ₹892.79 Cr | ₹1,140.74 Cr | ₹607.09 Cr |
| EBITDA (computed) | ₹2,153.01 Cr | ₹1,818.94 Cr | ₹1,445.93 Cr | ₹1,052.39 Cr | ₹1,375.83 Cr | ₹1,607.19 Cr | ₹973.7 Cr |
| Basic EPS | ₹44.98 | ₹29.08 | ₹21.57 | ₹18.58 | ₹34.85 | ₹90.11 | ₹47.77 |
| Diluted EPS | ₹44.98 | ₹29.08 | ₹21.57 | ₹18.58 | ₹34.85 | ₹90.11 | ₹47.73 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹12,370 Cr | ₹11,761 Cr | ₹11,101 Cr | ₹8,626.43 Cr |
| Non-current Assets | ₹5,993.33 Cr | ₹5,492.01 Cr | ₹5,562.38 Cr | ₹3,437.16 Cr |
| Current Assets | ₹6,373.61 Cr | ₹5,967.04 Cr | ₹5,535.55 Cr | ₹5,189.27 Cr |
| Property, Plant & Equipment | ₹4,440.59 Cr | ₹4,068.91 Cr | ₹4,339.51 Cr | ₹2,572.41 Cr |
| Inventories | ₹2,731 Cr | ₹2,560.42 Cr | ₹2,471.31 Cr | ₹1,743.37 Cr |
| Trade Receivables | ₹2,014.26 Cr | ₹1,873.82 Cr | ₹1,686.51 Cr | ₹989.02 Cr |
| Cash & Equivalents | ₹437.12 Cr | ₹167.17 Cr | ₹208.91 Cr | ₹1,257.85 Cr |
| Equity (Net Worth) | ₹9,524.06 Cr | ₹8,388.27 Cr | ₹7,727 Cr | ₹5,915.32 Cr |
| Equity Share Capital | ₹25.37 Cr | ₹25.37 Cr | ₹25.37 Cr | ₹25.37 Cr |
| Borrowings (Non-current) | ₹109.12 Cr | ₹543.24 Cr | ₹580.41 Cr | ₹651.78 Cr |
| Borrowings (Current) | ₹594.82 Cr | ₹758.46 Cr | ₹807.09 Cr | ₹805.75 Cr |
| Total Debt (computed) | ₹703.94 Cr | ₹1,301.7 Cr | ₹1,387.5 Cr | ₹1,457.53 Cr |
| Current Liabilities | ₹2,306.93 Cr | ₹2,384.29 Cr | ₹2,355.64 Cr | ₹1,805.82 Cr |
| Total Liabilities | ₹2,846.13 Cr | ₹3,372.28 Cr | ₹3,374.28 Cr | ₹2,711.11 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹1,141.97 Cr | ₹1,321.32 Cr | ₹944.65 Cr | ₹805.81 Cr | ₹856.04 Cr |
| Investing Cash Flow | -₹246.77 Cr | -₹869.5 Cr | -₹1,291.79 Cr | -₹725 Cr | -₹855.05 Cr |
| Financing Cash Flow | -₹753.53 Cr | -₹282.98 Cr | -₹552.55 Cr | ₹507.24 Cr | ₹426.81 Cr |
| Capital Expenditure | ₹652.26 Cr | ₹775.52 Cr | ₹411.29 Cr | ₹494.47 Cr | ₹478.95 Cr |
| Free Cash Flow (computed) | ₹489.71 Cr | ₹545.8 Cr | ₹533.36 Cr | ₹311.34 Cr | ₹377.09 Cr |
| Dividends Paid | ₹52.41 Cr | ₹101.48 Cr | ₹50.74 Cr | ₹101.48 Cr | ₹101.45 Cr |
| Net Change in Cash | ₹141.67 Cr | ₹168.84 Cr | -₹899.69 Cr | ₹588.05 Cr | ₹427.8 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹2,388.48 Cr | ₹2,392.5 Cr | ₹2,556.5 Cr | ₹2,308.85 Cr | ₹2,246.69 Cr | ₹2,245.37 Cr | ₹2,354.9 Cr | ₹2,092.63 Cr | ₹2,033.01 Cr | ₹2,052.86 Cr | ₹2,033.96 Cr | ₹1,587.58 Cr |
| Other Income | ₹93.74 Cr | ₹20.19 Cr | ₹27.86 Cr | ₹32.66 Cr | ₹25.82 Cr | ₹20.11 Cr | ₹26.26 Cr | ₹20.61 Cr | ₹18.92 Cr | ₹22.45 Cr | ₹38.55 Cr | ₹44.85 Cr |
| Total Income | ₹2,482.22 Cr | ₹2,412.69 Cr | ₹2,584.36 Cr | ₹2,341.51 Cr | ₹2,272.51 Cr | ₹2,265.48 Cr | ₹2,381.16 Cr | ₹2,113.24 Cr | ₹2,051.93 Cr | ₹2,075.31 Cr | ₹2,072.51 Cr | ₹1,632.43 Cr |
| Cost of Materials Consumed | ₹592.6 Cr | ₹564.44 Cr | ₹569.87 Cr | ₹617.1 Cr | ₹660.07 Cr | ₹482.44 Cr | ₹588.99 Cr | ₹545.32 Cr | ₹565.05 Cr | ₹609.95 Cr | ₹608.9 Cr | ₹432.42 Cr |
| Purchases of Stock-in-Trade | ₹149.22 Cr | ₹129.83 Cr | ₹126.83 Cr | ₹126.74 Cr | ₹86.98 Cr | ₹188.29 Cr | ₹153.83 Cr | ₹118.68 Cr | ₹108.57 Cr | ₹116.32 Cr | ₹144.09 Cr | ₹121.09 Cr |
| Changes in Inventories | -₹50.2 Cr | -₹36.37 Cr | ₹84.94 Cr | -₹52.28 Cr | -₹38.76 Cr | -₹2.52 Cr | ₹15.74 Cr | -₹20.51 Cr | ₹12.27 Cr | -₹29.32 Cr | -₹75.41 Cr | -₹38.18 Cr |
| Employee Benefit Expense | ₹533 Cr | ₹546.09 Cr | ₹537.94 Cr | ₹543.17 Cr | ₹500.84 Cr | ₹485.44 Cr | ₹509.84 Cr | ₹487.87 Cr | ₹466.01 Cr | ₹459.04 Cr | ₹425.87 Cr | ₹357.51 Cr |
| Finance Costs | ₹20.2 Cr | ₹17.62 Cr | ₹19.61 Cr | ₹18.51 Cr | ₹21.51 Cr | ₹16.81 Cr | ₹22.56 Cr | ₹24.05 Cr | ₹29.37 Cr | ₹33.4 Cr | ₹44.12 Cr | ₹31.38 Cr |
| Depreciation & Amortisation | ₹107.14 Cr | ₹107.59 Cr | ₹103.33 Cr | ₹100.06 Cr | ₹100.12 Cr | ₹98.46 Cr | ₹100.35 Cr | ₹98.89 Cr | ₹98.13 Cr | ₹99.5 Cr | ₹90.34 Cr | ₹69.27 Cr |
| Other Expenses | ₹679.99 Cr | ₹655.16 Cr | ₹692 Cr | ₹657.7 Cr | ₹608.7 Cr | ₹628.64 Cr | ₹645.02 Cr | ₹568.55 Cr | ₹559.21 Cr | ₹565.54 Cr | ₹609.24 Cr | ₹407.12 Cr |
| Total Expenses | ₹2,031.95 Cr | ₹1,984.36 Cr | ₹2,134.52 Cr | ₹2,011 Cr | ₹1,939.46 Cr | ₹1,897.56 Cr | ₹2,036.33 Cr | ₹1,822.85 Cr | ₹1,838.61 Cr | ₹1,854.43 Cr | ₹1,847.15 Cr | ₹1,380.61 Cr |
| Profit Before Exceptional Items & Tax | ₹450.27 Cr | ₹428.33 Cr | ₹449.84 Cr | ₹330.51 Cr | ₹333.05 Cr | ₹367.92 Cr | ₹344.83 Cr | ₹290.39 Cr | ₹213.32 Cr | ₹220.88 Cr | ₹225.36 Cr | ₹251.82 Cr |
| Exceptional Items | -₹45.82 Cr | ₹17.65 Cr | -₹58.26 Cr | ₹0 | -₹205.05 Cr | ₹0 | ₹0 | ₹0 | -₹136.72 Cr | ₹68.01 Cr | ₹0 | ₹0 |
| Profit Before Tax | ₹404.45 Cr | ₹445.98 Cr | ₹391.58 Cr | ₹330.51 Cr | ₹128 Cr | ₹367.92 Cr | ₹344.83 Cr | ₹290.39 Cr | ₹76.6 Cr | ₹288.89 Cr | ₹225.36 Cr | ₹251.82 Cr |
| Total Tax Expense | ₹95.05 Cr | ₹81.93 Cr | ₹108.08 Cr | ₹96.09 Cr | ₹62.22 Cr | ₹90.59 Cr | ₹99.39 Cr | ₹91.41 Cr | ₹73.69 Cr | ₹66.24 Cr | ₹87.92 Cr | ₹85.61 Cr |
| Net Profit | ₹306.69 Cr | ₹363.67 Cr | ₹280.53 Cr | ₹232.89 Cr | ₹63.99 Cr | ₹276.36 Cr | ₹245.75 Cr | ₹199.14 Cr | ₹1.33 Cr | ₹221 Cr | ₹136.49 Cr | ₹164.1 Cr |
| attributable to Owners | ₹299.07 Cr | ₹326.27 Cr | ₹282.57 Cr | ₹233.21 Cr | ₹67.82 Cr | ₹248.14 Cr | ₹229.48 Cr | ₹192.24 Cr | ₹59.59 Cr | ₹179.88 Cr | ₹145.06 Cr | ₹162.82 Cr |
| attributable to NCI | ₹7.62 Cr | ₹37.4 Cr | -₹2.04 Cr | -₹32 Lakh | -₹3.83 Cr | ₹28.22 Cr | ₹16.27 Cr | ₹6.9 Cr | -₹58.26 Cr | ₹41.12 Cr | -₹8.57 Cr | ₹1.28 Cr |
| Other Comprehensive Income | ₹27.33 Cr | -₹60 Lakh | ₹11.08 Cr | ₹4.95 Cr | -₹7.41 Cr | -₹12.64 Cr | -₹4.88 Cr | ₹38 Lakh | -₹8.48 Cr | ₹1.03 Cr | -₹76 Lakh | -₹1.24 Cr |
| Total Comprehensive Income | ₹334.02 Cr | ₹363.07 Cr | ₹291.61 Cr | ₹237.84 Cr | ₹56.58 Cr | ₹263.72 Cr | ₹240.87 Cr | ₹199.52 Cr | -₹7.15 Cr | ₹222.03 Cr | ₹135.73 Cr | ₹162.86 Cr |
| EBITDA (computed) | ₹577.61 Cr | ₹553.54 Cr | ₹572.78 Cr | ₹449.08 Cr | ₹454.68 Cr | ₹483.19 Cr | ₹467.74 Cr | ₹413.33 Cr | ₹340.82 Cr | ₹353.78 Cr | ₹359.82 Cr | ₹352.47 Cr |
| Basic EPS | ₹11.79 | ₹12.86 | ₹11.14 | ₹9.19 | ₹2.67 | ₹9.78 | ₹9.05 | ₹7.58 | ₹2.35 | ₹7.09 | ₹5.72 | ₹6.42 |
| Diluted EPS | ₹11.79 | ₹12.86 | ₹11.14 | ₹9.19 | ₹2.67 | ₹9.78 | ₹9.05 | ₹7.58 | ₹2.35 | ₹7.09 | ₹5.72 | ₹6.42 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue from Operations | ₹7,336.75 Cr | ₹6,677.92 Cr | ₹6,166.46 Cr | ₹5,814.62 Cr | ₹5,399.36 Cr | ₹4,367.43 Cr |
| Other Income | ₹94.64 Cr | ₹71.29 Cr | ₹111.29 Cr | ₹111.19 Cr | ₹56.13 Cr | ₹64.69 Cr |
| Total Income | ₹7,431.39 Cr | ₹6,749.21 Cr | ₹6,277.75 Cr | ₹5,925.81 Cr | ₹5,455.49 Cr | ₹4,432.12 Cr |
| Cost of Materials Consumed | ₹1,568.33 Cr | ₹1,417.64 Cr | ₹1,688.36 Cr | ₹1,684.03 Cr | ₹1,600.98 Cr | ₹1,431.1 Cr |
| Purchases of Stock-in-Trade | ₹348.51 Cr | ₹347.24 Cr | ₹345.21 Cr | ₹280.91 Cr | ₹282.9 Cr | ₹204.65 Cr |
| Changes in Inventories | -₹60.06 Cr | ₹128.43 Cr | -₹55.19 Cr | ₹104.09 Cr | -₹120.76 Cr | -₹155.05 Cr |
| Employee Benefit Expense | ₹1,655.9 Cr | ₹1,479.34 Cr | ₹1,336.19 Cr | ₹1,193.39 Cr | ₹1,089.63 Cr | ₹870.79 Cr |
| Finance Costs | ₹43.51 Cr | ₹63.04 Cr | ₹120.67 Cr | ₹43.92 Cr | ₹7.21 Cr | ₹15.79 Cr |
| Depreciation & Amortisation | ₹268.87 Cr | ₹251.97 Cr | ₹246.48 Cr | ₹228.63 Cr | ₹204.1 Cr | ₹178.69 Cr |
| Other Expenses | ₹2,043.78 Cr | ₹1,780.24 Cr | ₹1,640.51 Cr | ₹1,640.35 Cr | ₹1,303.07 Cr | ₹1,101.18 Cr |
| Total Expenses | ₹5,868.84 Cr | ₹5,467.9 Cr | ₹5,322.23 Cr | ₹5,175.32 Cr | ₹4,367.13 Cr | ₹3,647.15 Cr |
| Profit Before Exceptional Items & Tax | ₹1,562.55 Cr | ₹1,281.31 Cr | ₹955.52 Cr | ₹750.49 Cr | ₹1,088.36 Cr | ₹784.97 Cr |
| Exceptional Items | -₹30.42 Cr | -₹281.54 Cr | -₹133.36 Cr | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹1,532.13 Cr | ₹999.77 Cr | ₹822.16 Cr | ₹750.49 Cr | ₹1,088.36 Cr | ₹784.97 Cr |
| Total Tax Expense | ₹399.61 Cr | ₹349.01 Cr | ₹291.75 Cr | ₹244.79 Cr | ₹217.42 Cr | ₹132.51 Cr |
| Net Profit | ₹1,132.52 Cr | ₹650.76 Cr | ₹530.41 Cr | ₹505.7 Cr | ₹870.94 Cr | ₹652.46 Cr |
| Other Comprehensive Income | ₹5.95 Cr | -₹6.37 Cr | -₹8.26 Cr | -₹2.68 Cr | ₹1.16 Cr | -₹7.67 Cr |
| Total Comprehensive Income | ₹1,138.47 Cr | ₹644.39 Cr | ₹522.15 Cr | ₹503.02 Cr | ₹872.1 Cr | ₹644.79 Cr |
| EBITDA (computed) | ₹1,874.93 Cr | ₹1,596.32 Cr | ₹1,322.67 Cr | ₹1,023.04 Cr | ₹1,299.67 Cr | ₹979.45 Cr |
| Basic EPS | ₹44.64 | ₹25.65 | ₹20.91 | ₹19.39 | ₹34.33 | ₹51.64 |
| Diluted EPS | ₹44.64 | ₹25.65 | ₹20.91 | ₹19.39 | ₹34.33 | ₹51.60 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹9,775.5 Cr | ₹9,070.92 Cr | ₹8,659.27 Cr | ₹8,446.97 Cr |
| Non-current Assets | ₹5,780.5 Cr | ₹5,252.87 Cr | ₹5,149.38 Cr | ₹3,571.82 Cr |
| Current Assets | ₹3,995 Cr | ₹3,779.94 Cr | ₹3,509.89 Cr | ₹4,875.15 Cr |
| Property, Plant & Equipment | ₹2,934.82 Cr | ₹2,502.78 Cr | ₹2,502.09 Cr | ₹2,454.58 Cr |
| Inventories | ₹1,707.51 Cr | ₹1,542.39 Cr | ₹1,677.09 Cr | ₹1,660.13 Cr |
| Trade Receivables | ₹1,272.05 Cr | ₹1,154.61 Cr | ₹1,027.4 Cr | ₹925.9 Cr |
| Cash & Equivalents | ₹311.51 Cr | ₹76.77 Cr | ₹108.27 Cr | ₹1,183.7 Cr |
| Equity (Net Worth) | ₹7,979.35 Cr | ₹6,891.62 Cr | ₹6,348.71 Cr | ₹5,877.3 Cr |
| Equity Share Capital | ₹25.37 Cr | ₹25.37 Cr | ₹25.37 Cr | ₹25.37 Cr |
| Borrowings (Non-current) | ₹70 Cr | ₹482.43 Cr | ₹542.19 Cr | ₹651.78 Cr |
| Borrowings (Current) | ₹165.16 Cr | ₹389.3 Cr | ₹590.72 Cr | ₹770.83 Cr |
| Total Debt (computed) | ₹235.16 Cr | ₹871.73 Cr | ₹1,132.91 Cr | ₹1,422.61 Cr |
| Current Liabilities | ₹1,418.75 Cr | ₹1,417.6 Cr | ₹1,520.17 Cr | ₹1,677.78 Cr |
| Total Liabilities | ₹1,796.15 Cr | ₹2,179.3 Cr | ₹2,310.56 Cr | ₹2,569.67 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹1,378.12 Cr | ₹1,374.07 Cr | ₹830.51 Cr | ₹762.29 Cr | ₹840.14 Cr |
| Investing Cash Flow | -₹696.99 Cr | -₹738.81 Cr | -₹1,355.18 Cr | -₹709.61 Cr | -₹823.89 Cr |
| Financing Cash Flow | -₹745.21 Cr | -₹428.44 Cr | -₹464.88 Cr | ₹506.38 Cr | ₹426.1 Cr |
| Capital Expenditure | ₹665.45 Cr | ₹602.6 Cr | ₹360.22 Cr | ₹436.87 Cr | ₹446.01 Cr |
| Free Cash Flow (computed) | ₹712.67 Cr | ₹771.47 Cr | ₹470.29 Cr | ₹325.42 Cr | ₹394.13 Cr |
| Dividends Paid | ₹50.74 Cr | ₹101.48 Cr | ₹50.74 Cr | ₹101.48 Cr | ₹101.45 Cr |
| Net Change in Cash | -₹64.08 Cr | ₹206.82 Cr | -₹989.55 Cr | ₹559.06 Cr | ₹442.35 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹1,814.35 Cr | ₹1,845.18 Cr | ₹1,930.32 Cr | ₹1,746.9 Cr | ₹1,638.44 Cr | ₹1,662.68 Cr | ₹1,810.94 Cr | ₹1,565.86 Cr | ₹1,510.62 Cr | ₹1,506.83 Cr | ₹1,662.67 Cr | ₹1,488.71 Cr |
| Other Income | ₹29.88 Cr | ₹17.82 Cr | ₹21.92 Cr | ₹25.02 Cr | ₹21.49 Cr | ₹17.41 Cr | ₹17 Cr | ₹15.39 Cr | ₹15.1 Cr | ₹16.89 Cr | ₹36.14 Cr | ₹43.16 Cr |
| Total Income | ₹1,844.23 Cr | ₹1,863 Cr | ₹1,952.24 Cr | ₹1,771.92 Cr | ₹1,659.93 Cr | ₹1,680.09 Cr | ₹1,827.94 Cr | ₹1,581.25 Cr | ₹1,525.72 Cr | ₹1,523.72 Cr | ₹1,698.81 Cr | ₹1,531.87 Cr |
| Cost of Materials Consumed | ₹406.27 Cr | ₹389.15 Cr | ₹377.32 Cr | ₹395.59 Cr | ₹351.67 Cr | ₹352.01 Cr | ₹378.93 Cr | ₹335.03 Cr | ₹363.37 Cr | ₹411.25 Cr | ₹485.72 Cr | ₹428.02 Cr |
| Purchases of Stock-in-Trade | ₹85.03 Cr | ₹89.97 Cr | ₹89.4 Cr | ₹84.11 Cr | ₹79.06 Cr | ₹81.08 Cr | ₹94.76 Cr | ₹92.34 Cr | ₹78.14 Cr | ₹75.25 Cr | ₹100.13 Cr | ₹91.69 Cr |
| Changes in Inventories | -₹35.51 Cr | -₹36.67 Cr | ₹43.93 Cr | -₹31.81 Cr | ₹14.79 Cr | ₹26.17 Cr | ₹62.25 Cr | ₹25.22 Cr | ₹42.2 Cr | -₹1.11 Cr | -₹50.96 Cr | -₹45.32 Cr |
| Employee Benefit Expense | ₹413.53 Cr | ₹421.07 Cr | ₹411.39 Cr | ₹409.91 Cr | ₹377.12 Cr | ₹358.48 Cr | ₹382.44 Cr | ₹361.3 Cr | ₹333.22 Cr | ₹334.33 Cr | ₹336.15 Cr | ₹332.49 Cr |
| Finance Costs | ₹10.48 Cr | ₹9.51 Cr | ₹11.46 Cr | ₹12.06 Cr | ₹16.2 Cr | ₹10.17 Cr | ₹17.25 Cr | ₹19.42 Cr | ₹24.06 Cr | ₹27.21 Cr | ₹38.64 Cr | ₹30.76 Cr |
| Depreciation & Amortisation | ₹70.31 Cr | ₹68.57 Cr | ₹66.86 Cr | ₹63.13 Cr | ₹65.19 Cr | ₹62.81 Cr | ₹62.65 Cr | ₹61.32 Cr | ₹61.76 Cr | ₹63.02 Cr | ₹61.35 Cr | ₹60.35 Cr |
| Other Expenses | ₹513.85 Cr | ₹504.18 Cr | ₹543.57 Cr | ₹482.18 Cr | ₹457.21 Cr | ₹433.85 Cr | ₹490.45 Cr | ₹398.73 Cr | ₹401.35 Cr | ₹413.62 Cr | ₹482.65 Cr | ₹384.3 Cr |
| Total Expenses | ₹1,463.96 Cr | ₹1,445.78 Cr | ₹1,543.93 Cr | ₹1,415.17 Cr | ₹1,361.24 Cr | ₹1,324.57 Cr | ₹1,488.73 Cr | ₹1,293.36 Cr | ₹1,304.1 Cr | ₹1,323.57 Cr | ₹1,453.68 Cr | ₹1,282.29 Cr |
| Profit Before Exceptional Items & Tax | ₹380.27 Cr | ₹417.22 Cr | ₹408.31 Cr | ₹356.75 Cr | ₹298.69 Cr | ₹355.52 Cr | ₹339.21 Cr | ₹287.89 Cr | ₹221.62 Cr | ₹200.15 Cr | ₹245.13 Cr | ₹249.58 Cr |
| Exceptional Items | -₹30.42 Cr | ₹0 | ₹0 | ₹0 | -₹281.54 Cr | ₹0 | ₹0 | ₹0 | -₹94.32 Cr | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹349.85 Cr | ₹417.22 Cr | ₹408.31 Cr | ₹356.75 Cr | ₹17.15 Cr | ₹355.52 Cr | ₹339.21 Cr | ₹287.89 Cr | ₹127.3 Cr | ₹200.15 Cr | ₹245.13 Cr | ₹249.58 Cr |
| Total Tax Expense | ₹87.56 Cr | ₹113.77 Cr | ₹103.57 Cr | ₹94.71 Cr | ₹82.2 Cr | ₹87.96 Cr | ₹95.09 Cr | ₹83.76 Cr | ₹62.54 Cr | ₹63.21 Cr | ₹83 Cr | ₹83 Cr |
| Net Profit | ₹262.29 Cr | ₹303.45 Cr | ₹304.74 Cr | ₹262.04 Cr | -₹65.05 Cr | ₹267.56 Cr | ₹244.12 Cr | ₹204.13 Cr | ₹64.76 Cr | ₹136.94 Cr | ₹162.13 Cr | ₹166.58 Cr |
| Other Comprehensive Income | ₹5.98 Cr | -₹7 Lakh | ₹1.93 Cr | -₹1.89 Cr | ₹2.57 Cr | -₹1.31 Cr | -₹7.64 Cr | ₹1 Lakh | -₹6.83 Cr | -₹65 Lakh | -₹31 Lakh | -₹47 Lakh |
| Total Comprehensive Income | ₹268.27 Cr | ₹303.38 Cr | ₹306.67 Cr | ₹260.15 Cr | -₹62.48 Cr | ₹266.25 Cr | ₹236.48 Cr | ₹204.14 Cr | ₹57.93 Cr | ₹136.29 Cr | ₹161.82 Cr | ₹166.11 Cr |
| EBITDA (computed) | ₹461.06 Cr | ₹495.3 Cr | ₹486.63 Cr | ₹431.94 Cr | ₹380.08 Cr | ₹428.5 Cr | ₹419.11 Cr | ₹368.63 Cr | ₹307.44 Cr | ₹290.38 Cr | ₹345.12 Cr | ₹340.69 Cr |
| Basic EPS | ₹10.34 | ₹11.96 | ₹12.01 | ₹10.33 | ₹-2.56 | ₹10.55 | ₹9.62 | ₹8.05 | ₹2.55 | ₹5.40 | ₹6.39 | ₹6.57 |
| Diluted EPS | ₹10.34 | ₹11.96 | ₹12.01 | ₹10.33 | ₹-2.56 | ₹10.55 | ₹9.62 | ₹8.05 | ₹2.55 | ₹5.40 | ₹6.39 | ₹6.57 |
Shareholding Pattern of Ipca Laboratories Limited
As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 44.72%, foreign institutional investors hold 10.63%, domestic institutional investors hold 37.45%, retail and other public shareholders hold 7.20% of Ipca Laboratories Limited. The company had 82,184 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 44.72% | 44.72% | 44.72% | 44.72% | 44.72% | 44.72% |
| Public | 55.28% | 55.28% | 55.28% | 55.28% | 55.28% | 55.28% |
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 44.72% | 44.72% | 46.30% | 46.29% | 46.29% | 46.29% | 46.07% | 46.07% | 46.13% | 46.13% | 45.89% |
| Public | 55.28% | 55.28% | 53.70% | 53.71% | 53.71% | 53.71% | 53.93% | 53.93% | 53.87% | 53.87% | 54.11% |
| Promoter change (YoY, %pts) | +0.00 | -1.58 | +0.01 | +0.00 | +0.00 | +0.22 | +0.00 | -0.06 | +0.00 | +0.24 | - |
Board & Governance of Ipca Laboratories Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Ipca Laboratories Limited has 8 directors - 4 independent and 4 executive. The board is chaired by Premchand Godha.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| Premchand Godha | Executive Director · Chairperson | 1975-10-31 | 1 |
| A. K. Jain | Executive Director · MD | 1994-08-21 | 1 |
| Pranay Godha | Executive Director · CEO-MD | 2008-11-11 | 2 |
| Prashant Godha | Executive Director | 2011-07-28 | 4 |
| Narendra Mairpady | Non-Executive - Independent Director | 2022-10-20 | 5 |
| Kamal Kishore Seth | Non-Executive - Independent Director | 2019-03-29 | 2 |
| Swati Patankar | Non-Executive - Independent Director | 2024-02-14 | 2 |
| Vivek Keshav Shiralkar | Non-Executive - Independent Director | 2024-05-29 | 2 |
| Committee | Members |
|---|---|
| Audit Committee | Kamal Kishore Seth (Chairperson), Narendra Mairpady, Prashant Godha, Swati Patankar, Vivek Keshav Shiralkar |
| Nomination and remuneration committee | Narendra Mairpady (Chairperson), Kamal Kishore Seth, Swati Patankar, Vivek Keshav Shiralkar |
| Stakeholders Relationship Committee | Kamal Kishore Seth (Chairperson), Premchand Godha, A. K. Jain, Vivek Keshav Shiralkar |
| Risk Management Committee | Kamal Kishore Seth (Chairperson), A. K. Jain, Pranay Godha, Prashant Godha, Manish Jain |
| Corporate Social Responsibility Committee | Kamal Kishore Seth (Chairperson), Premchand Godha, A. K. Jain, Prashant Godha |
Group Structure of Ipca Laboratories Limited
Ipca Laboratories Limited has 3 subsidiary companies, 2 joint ventures, and 3 associated companies. This group structure data is as of FY 2024. The corporate group structure reflects Ipca Laboratories Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Unichem Laboratories Limited | L99999MH1962PLC012451 | - |
| Trophic Wellness Private Limited | U24100MH2010PTC206526 | - |
| Ipca Foundation | U85300MH2021NPL360586 | - |
Showing major subsidiaries. Total: 3.
Charges & Borrowings of Ipca Laboratories Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 24 Jan 2025 | Citi Bank N.A. | ₹166.6 Cr | Open |
| 29 Aug 2023 | Hdfc Bank Limited | ₹300 Cr | Open |
| 08 Aug 2023 | The Hongkong and Shanghai Banking Corporation Limited | ₹123.71 Cr | Open |
| 07 Oct 2022 | Hdfc Bank Limited | ₹391.22 Cr | Open |
| 02 Aug 2022 | Jp Morgan Chase Bank, N.A. | ₹114.21 Cr | Open |
Total charge records: 108 View all charges
Employees and EPFO Compliance at Ipca Laboratories Limited
Ipca Laboratories Limited has a workforce of 17,422 employees as of Feb 28, 2025.
Employee Count & EPFO Data of Ipca Laboratories Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Ipca Laboratories Limited
GSTIN & GST Filing Data of Ipca Laboratories Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Ipca Laboratories Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Ipca Laboratories Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Ipca Laboratories Limited
MSME Payment Delays by Ipca Laboratories Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Ipca Laboratories Limited
Subsidiaries & Group Companies of Ipca Laboratories Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Ipca Laboratories Limited with ownership details.
MCA Filings & Documents of Ipca Laboratories Limited
MCA Filings & Documents of Ipca Laboratories Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Ipca Laboratories Limited
Recent News on Ipca Laboratories Limited
Frequently Asked Questions about Ipca Laboratories Limited
Ipca Laboratories Limited is an active public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 19 October 1949 (77+ years old) and is registered under CIN L24239MH1949PLC007837. Listed on BSE: 524494 and NSE: IPCALAB. The company has 17,422 employees.
Ipca Laboratories Limited reported revenue of ₹9,032.39 Cr for FY 2025 (up 15.00% YoY).
The current directors of Ipca Laboratories Limited are:
- Vivek Keshav Shiralkar
- Pranay Premchand Godha
- Harish Pandurang Kamath
- Ajit Kumar Jain
- Prashant Premchand Godha
- Narendra Mairpady
- Premchand Gigalal Godha
- Swati Arvind Patankar
- Kamal Kishore Seth
The primary industry of Ipca Laboratories Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes. Ipca Laboratories Limited is listed on both BSE (code: 524494) and NSE (symbol: IPCALAB).
Ipca Laboratories Limited can be reached at the registered office: 48 Kandivli Industrialestate Kandivali W, Mumbai, Maharashtra, India – 400067, or through the website ipca.com.